Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults
Status:
Completed
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to compare the single-dose relative bioavailability
of Alpharma Branded Products Division (Kadian®) and Ligand® Pharmaceuticals Inc. (AVINZA®) 30
mg morphine sulfate sustained-release capsules in healthy adult volunteers under fed
conditions.
The secondary objective of this study was to evaluate the adverse events associated with each
of these 2 different morphine sulfate modified-release commercial formulations
Phase:
Phase 4
Details
Lead Sponsor:
Actavis Inc. Alpharma Pharmaceuticals LLC, a subsidiary of Pfizer Inc.